---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-155612"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:48:48.953031+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vaccinex completes last patient visit in SIGNAL-AD Phase 1b/2 Alzheimer's study

## Summary
- Last patient completed final visit in randomized, double-blind Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease.
- Database lock expected in June; key outcomes including safety, FDG-PET, and plasma GFAP biomarkers to be reported in July.
- Pepinemab targets SEMA4D to inhibit astrocyte reactivity and neuroinflammation, a differentiated mechanism vs. anti-amyloid antibodies.
- Study funded by $4.75M from ADDF and $0.75M grant from Alzheimer's Association.

## SEC filing metadata
- accession: 0001193125-24-155612
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312524155612/0001193125-24-155612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312524155612/d756458d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-155612
- JSON: https://secwatch.observer/filing/0001193125-24-155612.json
- Plain text: https://secwatch.observer/filing/0001193125-24-155612.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.